These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 8244163

  • 1. Ifosfamide and mesna in epithelial ovarian carcinoma.
    Sutton G.
    Gynecol Oncol; 1993 Oct; 51(1):104-8. PubMed ID: 8244163
    [Abstract] [Full Text] [Related]

  • 2. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
    Markman M, Hakes T, Reichman B, Lewis JL, Rubin S, Jones W, Almadrones L, Pizzuto F, Hoskins W.
    J Clin Oncol; 1992 Feb; 10(2):243-8. PubMed ID: 1732425
    [Abstract] [Full Text] [Related]

  • 3. Ifosfamide in non-small cell lung cancer.
    Johnson DH.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):7-10. PubMed ID: 8677453
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide in the treatment of soft tissue sarcomas.
    Connelly EF, Budd GT.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
    [Abstract] [Full Text] [Related]

  • 5. Ifosfamide and mesna.
    Schoenike SE, Dana WJ.
    Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
    [Abstract] [Full Text] [Related]

  • 7. Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
    Dorval T, Soussain C, Beuzeboc P, Garcia-Giralt E, Jouve M, Livartowski A, Mosseri V, Palangié T, Scholl S, Sastre X, Pouillart P.
    J Infus Chemother; 1996 Feb; 6(1):47-9. PubMed ID: 8748008
    [Abstract] [Full Text] [Related]

  • 8. High dose ifosfamide with mesna uroprotection.
    Cerny T.
    Pathol Biol (Paris); 1993 Jan; 41(1):102. PubMed ID: 8316441
    [No Abstract] [Full Text] [Related]

  • 9. Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer.
    Vallejos C, Solidoro A, Gómez H, Castellano C, Barriga O, Galdos R, Casanova L, Otero J, Rodriguez W.
    Gynecol Oncol; 1997 Nov; 67(2):168-71. PubMed ID: 9367702
    [Abstract] [Full Text] [Related]

  • 10. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
    Markman M, Kennedy A, Sutton G, Hurteau J, Webster K, Peterson G, Kulp B, Belinson J.
    Gynecol Oncol; 1998 Aug; 70(2):272-4. PubMed ID: 9740704
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
    Sutton GP, Blessing JA, DiSaia PJ, McGuire WP.
    Gynecol Oncol; 1993 Apr; 49(1):48-50. PubMed ID: 8482560
    [Abstract] [Full Text] [Related]

  • 12. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
    Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J.
    J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
    [Abstract] [Full Text] [Related]

  • 13. Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
    Falkson CI, Falkson HC, Falkson G.
    Invest New Drugs; 1989 Jul; 7(2-3):261-7. PubMed ID: 2507474
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A, Kosmas C, Tsavaris N, Toufexi H, Lagadas A, Gogas H, Giannakopoulos K, Kouraklis G, Griniatsos J, Felekouras E, Tsigris C, Nikiteas N, Papadopoulos O, Giannopoulos A.
    Anticancer Res; 2007 Jul; 27(3B):1645-51. PubMed ID: 17595790
    [Abstract] [Full Text] [Related]

  • 15. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J, Kellner R, Seeber S.
    Cancer Chemother Pharmacol; 1993 Jul; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [Abstract] [Full Text] [Related]

  • 16. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen.
    González-Martín A, Crespo C, García-López JL, Pedraza M, Garrido P, Lastra E, Moyano A.
    Gynecol Oncol; 2002 Mar; 84(3):368-73. PubMed ID: 11855871
    [Abstract] [Full Text] [Related]

  • 17. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium.
    Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC.
    Gynecol Oncol; 1996 Oct; 63(1):25-7. PubMed ID: 8898163
    [Abstract] [Full Text] [Related]

  • 18. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Oct; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 19. Ifosfamide in the treatment of ovarian cancer.
    Markman M.
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):47-9. PubMed ID: 8677449
    [Abstract] [Full Text] [Related]

  • 20. Ifosfamide combination regimens for soft-tissue sarcoma.
    Stuart-Harris R, Dalley D, Bell DR, Levi J, Simes RJ, Wiltshaw E.
    Cancer Chemother Pharmacol; 1993 Jun; 31 Suppl 2():S185-8. PubMed ID: 8453695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.